CRISPR Therapeutics AG
CRSPNASDAQHealthcare● Active
$51.60
$-0.24(-0.46%)
Market Cap$5.0B
P/E Ratio—
52W High$78.48
52W Low$37.02
CRISPR Therapeutics AG (CRSP) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
CRSP · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 4, 2026EPS Actual
-$1.28
Est. -$1.18 · -8.2%
Revenue
$0.00B
Est. $0.01B · -76.0%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 4, 2026
After Market Close
▼ Miss EPS▼ Miss Revenue
CRSP reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.36
Rev. $5.58B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.36
Rev. Est.$5.58B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 3, 2026 | -$1.20 | — | — | — | $0.01B | — |
| ▼ Q2 FY2026 | May 4, 2026 | -$1.18 | -$1.28 | -8.2% | $0.00B | $0.01B | -76.0% |
| ▼ Q1 FY2026 | Feb 12, 2026 | -$1.15 | -$1.37 | -19.1% | $0.00B | $0.00B | -81.7% |
| ▲ Q4 FY2025 | Nov 10, 2025 | -$1.26 | -$1.17 | +7.1% | $0.00B | $0.01B | -90.3% |
| ▲ Q3 FY2025 | Aug 4, 2025 | -$1.47 | -$1.29 | +12.2% | $0.00B | $0.01B | -90.5% |
| ▼ Q2 FY2025 | May 6, 2025 | -$1.27 | -$1.58 | -24.4% | $0.00B | $0.01B | -85.5% |
| ▲ Q1 FY2025 | Feb 11, 2025 | -$1.15 | -$0.44 | +61.7% | $0.04B | $0.01B | +334.5% |
| ▲ Q4 FY2024 | Nov 5, 2024 | -$1.33 | -$1.01 | +24.1% | $0.00B | $0.01B | -92.2% |
Q3 FY2026
Aug 3, 2026
EPS Actual
—
EPS Est.
-$1.20
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 4, 2026Miss
EPS Actual
-$1.28
EPS Est.
-$1.18
EPS Surpr.
-8.2%
Revenue
$0.00B
Q1 FY2026
Feb 12, 2026Miss
EPS Actual
-$1.37
EPS Est.
-$1.15
EPS Surpr.
-19.1%
Revenue
$0.00B
Q4 FY2025
Nov 10, 2025Beat
EPS Actual
-$1.17
EPS Est.
-$1.26
EPS Surpr.
+7.1%
Revenue
$0.00B
Q3 FY2025
Aug 4, 2025Beat
EPS Actual
-$1.29
EPS Est.
-$1.47
EPS Surpr.
+12.2%
Revenue
$0.00B
Q2 FY2025
May 6, 2025Miss
EPS Actual
-$1.58
EPS Est.
-$1.27
EPS Surpr.
-24.4%
Revenue
$0.00B
Q1 FY2025
Feb 11, 2025Beat
EPS Actual
-$0.44
EPS Est.
-$1.15
EPS Surpr.
+61.7%
Revenue
$0.04B
Q4 FY2024
Nov 5, 2024Beat
EPS Actual
-$1.01
EPS Est.
-$1.33
EPS Surpr.
+24.1%
Revenue
$0.00B
Analyst Estimates
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-3.17 | $-0.75 | $0.18 | 5 |
| Q3 FY2027 | $-3.21 | $-0.76 | $0.18 | 5 |
| Q2 FY2027 | $-3.33 | $-0.79 | $0.19 | 5 |
| Q1 FY2027 | $-3.65 | $-0.87 | $0.21 | 5 |
| Q4 FY2026 | $-5.17 | $-1.23 | $0.29 | 10 |
| Q3 FY2026 | $-1.35 | $-1.20 | $-1.02 | 12 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.1B | 5 |
| Q3 FY2027 | $0.0B | $0.0B | $0.1B | 9 |
| Q2 FY2027 | $0.0B | $0.0B | $0.1B | 6 |
| Q1 FY2027 | $0.0B | $0.0B | $0.1B | 5 |
| Q4 FY2026 | $0.0B | $0.0B | $0.1B | 5 |
| Q3 FY2026 | $0.0B | $0.0B | $0.1B | 11 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 4, 2026 | -8.2% | $51.63 | $53.58 | +3.78% |
| ▼ Q1 FY2026 | Feb 12, 2026 | -19.1% | $48.32 | $48.93 | +1.26% |
| ▲ Q4 FY2025 | Nov 10, 2025 | +7.1% | $55.12 | $54.58 | -0.98% |
| ▲ Q3 FY2025 | Aug 4, 2025 | +12.2% | $56.09 | $59.59 | +6.24% |
| ▼ Q2 FY2025 | May 6, 2025 | -24.4% | $37.62 | $33.16 | -11.86% |
| ▲ Q1 FY2025 | Feb 11, 2025 | +61.7% | $39.41 | $39.62 | +0.53% |
| ▲ Q4 FY2024 | Nov 5, 2024 | +24.1% | $50.59 | $50.36 | -0.45% |
| ▼ Q3 FY2024 | Aug 5, 2024 | -8.8% | $51.11 | $49.66 | -2.84% |
Q2 FY2026+3.78%
Report Date
May 4, 2026
EPS Beat/Miss
-8.2%
Price Before
$51.63
Price After
$53.58
Q1 FY2026+1.26%
Report Date
Feb 12, 2026
EPS Beat/Miss
-19.1%
Price Before
$48.32
Price After
$48.93
Q4 FY2025-0.98%
Report Date
Nov 10, 2025
EPS Beat/Miss
+7.1%
Price Before
$55.12
Price After
$54.58
Q3 FY2025+6.24%
Report Date
Aug 4, 2025
EPS Beat/Miss
+12.2%
Price Before
$56.09
Price After
$59.59
Q2 FY2025-11.86%
Report Date
May 6, 2025
EPS Beat/Miss
-24.4%
Price Before
$37.62
Price After
$33.16
Q1 FY2025+0.53%
Report Date
Feb 11, 2025
EPS Beat/Miss
+61.7%
Price Before
$39.41
Price After
$39.62
Q4 FY2024-0.45%
Report Date
Nov 5, 2024
EPS Beat/Miss
+24.1%
Price Before
$50.59
Price After
$50.36
Q3 FY2024-2.84%
Report Date
Aug 5, 2024
EPS Beat/Miss
-8.8%
Price Before
$51.11
Price After
$49.66
Avg Beat Reaction+1.33%
Avg Miss Reaction-2.42%
Beat Rate4 / 8 quarters
Largest Move-11.86% (Q2 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: CRSP ends December
CRISPR Therapeutics AG (CRSP) most recently reported earnings on May 4, 2026 for Q2 FY2026, posting EPS of $-1.28 — missing the analyst consensus of $-1.18 by -8.2%. The next CRSP earnings date is expected around September 1, 2026.
Each quarter, investors track CRSP earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. CRSP revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
CRSP's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
CRSP earnings · 5 questionsCRISPR Therapeutics AG's next earnings report is expected around September 1, 2026. CRSP typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; CRSP historically reports after market close (AMC).
CRSP earnings datewhen is CRSP earningsCRSP next earnings datewhen does CRSP report earningsCRSP earnings calendar
▸ Source: FMP · CRISPR Therapeutics AG SEC filings · US GAAP · CRISPR Therapeutics AG SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026